Eye - commissioning policies
Please click on the links below to access the commissioning policies. The associated Equality Impact Assessments, if currently available, are accessible here.
The CCGs’ position on the implementation of policies affecting patient referral can be found here.
- Anti-vascular endothelial growth factors for use prior to vitrectomy in patients with proliferative diabetic retinopathy
- Bevacizumab for the first line treatment of neovascular (wet) age related macular degeneration
- Intravitreal bevacizumab for the management of rubeosis iridis and neovascular glaucoma
- Intravitreal bevacizumab for the management of radiation maculopathy
- Botulinum Toxin A for the management of blepharospasm and the management of hemifacial spasm (see central nervous system commissioning policies, click here)
Patients diagnosed with blepharospasm should be advised to check with the Driver and Vehicle Licensing Agency (DVLA) the requirements for notification and assessment with regard to continuing their licence to drive.
To access the accompanying Clinical policy patient support information for the cataract surgery policy please click here.
Please note: Some commissioning policies approved by the previous commissioning organisations have not been reviewed and updated yet. However they are still applicable for the local population and can be accessed here.
Consideration of treatment options for chronic eye conditions in the NHS
Please find two letters below regarding consideration of treatment options for chronic eye conditions in the NHS.
These have been sent to the Right Honourable Jeremy Hunt MP, Secretary of State for Health and Mr Simon Stevens, Chief Executive of NHS England.